IP Library › Granted Patent US 12,058,996
Granted Patent B2
US 12,058,996 · App. 16/622,457 · Granted Aug 13, 2024

High subzero cryopreservation

Inventors: Mehmet Toner (Charlestown, MA); Mustafa Korkut Uygun (Newton, MA); Shannon N. Tessier (Framingham, MA); Shannon L. Stott (Stoneham, MA); Lindong Weng (Arlington, MA); Reinier Johan De Vries (Boston, MA); Casie A. Pendexter (Rockland, MA); Stephanie E J Cronin (Boston, MA)
Assignee: The General Hospital Corporation
A01N1/0221A01N1/0294
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,058,996
App. No.
16/622,457
Granted
Aug 13, 2024
Kind
B2
Abstract

This disclosure is related to methods of preserving biological samples, organs, and organisms. This disclosure is based, at least in part, on the discovery that in the presence of heterogenous extracellular ice, endothelial cells have improved attachment and viability after preservation, and particularly by uniformly nucleating ice across the microvasculature using ice nucleating agents, the chance of intracelluar ice formation can be significantly reduced.

Claims (28)

1. A method for partially freezing a cell, the method comprising:

(a) incubating the cell in a loading solution comprising 3-O-methyl-D-glucopyranose (3-OMG) in a vessel, wherein a concentration of 3-OMG in the loading solution is from about 50 mM to about 200 mM, and wherein the cell is incubated at about 37° C. for about 2 hours;

(b) perfusing the vessel with a storage solution, wherein perfusing the vessel with the storage solution replaces the loading solution with the storage solution, wherein the storage solution comprises 3-OMG, one or more cryoprotective agents, and an ice nucleator, and wherein a concentration of 3-OMG in the storage solution is from about 50 mM to about 200 mM; and

(c) cooling the cell in the vessel to a temperature from −5° C. to −10° C., thereby partially freezing the storage solution in the vessel,

wherein from about 20% to about 99% of the storage solution in the vessel is in a solid state comprising extracellular ice crystals,

wherein the storage solution remains partially frozen during storage,

wherein the method avoids intracellular ice formation, and

wherein the method does not include vitrification.

2. The method of claim 1 , wherein the cell is a mammalian cell, and the method further comprises attaching the cell to the vessel.

3. The method of claim 2 , wherein the vessel is coated with fibronectin.

4. The method of claim 1 , wherein the vessel is a capillary tube.

5. The method of claim 1 , wherein the loading solution comprises EBM-2 complete media and 3-OMG.

6. The method of claim 1 , wherein the storage solution further comprises University of Wisconsin cold storage solution, wherein the University of Wisconsin cold storage solution comprises

about 100 mM potassium lactobionate,

about 25 mM KH2PO4,

about 5 mM MgSO4,

about 30 mM raffinose,

about 5 mM adenosine,

about 3 mM glutathione,

about 1 mM allopurinol, and

about 50 g/L hydroxyethyl starch.

7. The method of claim 1 , wherein the ice nucleator is InaZ of Pseudomonas syringae , and the one or more cryoprotective agents are selected from the group consisting of a sugar, glycerol, ethylene glycol, propylene glycol, polyethylene glycol (PEG), 1,2-propanediol, trehalose, and dimethyl sulfoxide (DMSO).

8. The method of claim 1 , wherein the storage solution further comprises trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), 3-O-methyl-D-glucopyranose, and polyethylene glycol (PEG).

9. The method of claim 8 , wherein the storage solution further comprises glycerol and trehalose.

10. The method of claim 1 , wherein the cell is partially frozen for more than 50 hours.

11. The method of claim 1 , wherein the cell is a human, porcine, murine, or bovine cell.

12. The method of claim 1 , wherein the cell is an oocyte, a sperm, a stem cell, an embryo, a zygote, or an endothelial cell.

13. The method of claim 1 , wherein the storage solution comprises about 25 mM trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), about 5% DMSO, and about 0.1 g/L InaZ of Pseudomonas syringae.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: TONER, MEHMET; UYGUN, MUSTAFA KORKUT; TESSIER, SHANNON N.; STOTT, SHANNON L.; WENG, LINDONG; DE VRIES, REINIER; PENDEXTER, CASIE A.; CRONIN, STEPHANIE EJ
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 053870/0454 →
Continuity (3)
Provisional Application 62541305 · Aug 4, 2017
Provisional Application 62519452 · Jun 14, 2017
Related Publication 20200154697A1 · May 21, 2020
Cited By (1)
US 12,616,191